
Daniela Pugliese

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1403887/publications.pdf Version: 2024-02-01



DANIELA PLICHESE

#	Article	IF	CITATIONS
1	Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: An open-label pilot study. Journal of Crohn's and Colitis, 2013, 7, e623-e629.	0.6	85
2	Management of perianal fistulas in Crohn's disease: An up-to-date review. World Journal of Gastroenterology, 2015, 21, 1394.	1.4	82
3	Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Review of Clinical Immunology, 2017, 13, 223-233.	1.3	78
4	Adalimumab in active ulcerative colitis: A "real-life―observational study. Digestive and Liver Disease, 2013, 45, 738-743.	0.4	72
5	Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents. Journal of Crohn's and Colitis, 2013, 7, 113-119.	0.6	68
6	Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. International Journal of Colorectal Disease, 2011, 26, 1435-1444.	1.0	66
7	Infliximab in Steroid-dependent Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 1065-1072.	0.9	66
8	Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. Digestive and Liver Disease, 2014, 46, 974-979.	0.4	64
9	Effectiveness and Safety of Vedolizumab in Anti-TNF-NaÃ⁻ve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study. Inflammatory Bowel Diseases, 2018, 24, 2442-2451.	0.9	56
10	Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis. Inflammatory Bowel Diseases, 2014, 20, 1368-1374.	0.9	55
11	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases, 2019, 25, 568-579.	0.9	51
12	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. Journal of Crohn's and Colitis, 2018, 12, 1079-1088.	0.6	50
13	Fecal HMCB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission. Inflammatory Bowel Diseases, 2016, 22, 2886-2893.	0.9	42
14	Frontiers in Drug Research and Development for Inflammatory Bowel Disease. Frontiers in Pharmacology, 2017, 8, 400.	1.6	40
15	Impact of COVIDâ€19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a highâ€volume Italian inflammatory bowel disease centre. United European Gastroenterology Journal, 2020, 8, 775-781.	1.6	40
16	Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 335-339.	0.6	37
17	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study― Digestive and Liver Disease, 2017, 49, 17-23.	0.4	35
18	The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. Inflammatory Bowel Diseases, 2020, 26, 1306-1314.	0.9	35

DANIELA PUGLIESE

#	Article	IF	CITATIONS
19	Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110066.	1.4	34
20	Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmunity Reviews, 2021, 20, 102832.	2.5	34
21	FOXP3 ⁺ T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF <mml:math <br="" xmlns:mml="http://www.w3.org/1998/Math/MathML">id="M1"><mml:mrow><mml:mi mathvariant="bold-italic">α</mml:mi></mml:mrow></mml:math> Agents. BioMed Research International. 2013. 2013. 1-10.	0.9	31
22	Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. United European Gastroenterology Journal, 2019, 7, 1189-1197.	1.6	31
23	Update on the management of inflammatory bowel disease: specific role of adalimumab. Clinical and Experimental Gastroenterology, 2011, 4, 163.	1.0	29
24	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. Digestive and Liver Disease, 2019, 51, 972-977.	0.4	25
25	Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the <scp>IGâ€IBD LIVE</scp> study. Alimentary Pharmacology and Therapeutics, 2022, 56, 95-109.	1.9	25
26	The role of multimodal treatment in Crohn′s disease patients with perianal fistula: a multicentre retrospective cohort study. Alimentary Pharmacology and Therapeutics, 2018, 48, 941-950.	1.9	24
27	Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2021, 10, 853.	1.0	22
28	Anti-TNF alpha in the treatment of ulcerative colitis: A valid approach for organ-sparing or an expensive option to delay surgery?. World Journal of Gastroenterology, 2014, 20, 4839.	1.4	22
29	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Digestive and Liver Disease, 2022, 54, 440-451.	0.4	22
30	Ileal Crohn's disease: CEUS determination of activity. Abdominal Imaging, 2012, 37, 359-368.	2.0	21
31	Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Digestive and Liver Disease, 2019, 51, 510-515.	0.4	18
32	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. Advances in Therapy, 2018, 35, 545-562.	1.3	16
33	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. United European Gastroenterology Journal, 2020, 8, 1228-1235.	1.6	16
34	Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. RMD Open, 2018, 4, e000667.	1.8	15
35	Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. Expert Review of Clinical Immunology, 2018, 14, 751-759.	1.3	14
36	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease â€~AGED' study. European Journal of Gastroenterology and Hepatology, 2019, 31, 1361-1369.	0.8	14

DANIELA PUGLIESE

#	Article	IF	CITATIONS
37	Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases. Expert Opinion on Biological Therapy, 2015, 15, 1107-1117.	1.4	13
38	Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. Journal of Gastrointestinal and Liver Diseases, 2013, 22, 21-5.	0.5	13
39	Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach. Italian Journal of Pediatrics, 2021, 47, 18.	1.0	12
40	Longâ€ŧerm outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. United European Gastroenterology Journal, 2021, 9, 507-516.	1.6	11
41	Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology, 2019, 58, 1113-1115.	0.9	9
42	Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab. Drug Design, Development and Therapy, 2013, 7, 289.	2.0	8
43	Twoâ€year effectiveness and safety of golimumab in ulcerative colitis: An IGâ€ŀBD study. United European Gastroenterology Journal, 2021, 9, 102-109.	1.6	8
44	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. Journal of Clinical Medicine, 2021, 10, 2914.	1.0	8
45	Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. Gastroenterology Research and Practice, 2018, 2018, 1-7.	0.7	7
46	Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. Digestive and Liver Disease, 2020, 52, 44-50.	0.4	7
47	Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211022.	1.4	7
48	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. Inflammatory Bowel Diseases, 2020, 26, e134-e136.	0.9	6
49	What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 387.	0.6	6
50	Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. Current Medical Research and Opinion, 2020, 36, 7-8.	0.9	5
51	Difference in treatment outcomes between clinical trials and "realâ€life―clinical practice: ustekinumab in ulcerative colitis. United European Gastroenterology Journal, 2020, 8, 11-12.	1.6	5
52	The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When "non-urgent― does not mean "deferrable― Digestive and Liver Disease, 2020, 52, 1238-1240.	0.4	4
53	Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. Minerva Gastroenterologica E Dietologica, 2020, 65, 280-290.	2.2	4
54	Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug, Healthcare and Patient Safety, 2016, 8, 1.	1.0	3

DANIELA PUGLIESE

#	Article	IF	Citations
55	Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients. Expert Opinion on Biological Therapy, 2021, 21, 97-104.	1.4	3
56	Editorial: withdrawal of anti TNFâ€alpha ―are we ready for biological therapy cycling?. Alimentary Pharmacology and Therapeutics, 2021, 54, 84-85.	1.9	3
57	Adalimumab for ulcerative colitis—is the glass half empty or half full?. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 249-251.	8.2	2
58	Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. Digestive and Liver Disease, 2021, , .	0.4	2
59	342 Retreatment With Infliximab in Inflammatory Bowel Disease: Tolerability and Effectiveness of Different Re-Induction Regimens. Gastroenterology, 2014, 146, S-78-S-79.	0.6	1
60	Reply to Managing Patients with Ulcerative Colitis with Infliximab in Primary and Referral Gastroenterology Centers. Inflammatory Bowel Diseases, 2014, 20, E25.	0.9	0
61	The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases. Expert Opinion on Biological Therapy, 2019, 19, 967-969.	1.4	0
62	Patient-Reported Outcomes for the Assessment of Sexual Health Among Patients Affected by Inflammatory Bowel Disease. Reviews on Recent Clinical Trials, 2022, 17, 250-258.	0.4	0